Key result
Although prescription approval rates for PCSK9i and BA have increased to >80%, the majority of US clinicians prescribing lipid-lowering therapies have never prescribed them.
Observational
Answers are grounded in this paper and cite their sources.
Despite high prescription approval rates (>80%), the majority of US clinicians have never prescribed novel lipid-lowering therapies, highlighting a need for interventions to increase clinician uptake.
The majority of US clinicians prescribing LLT have never prescribed a PCSK9i or BA, and among those who do, most have used these therapies in only a few patients. However, there exist distinct groups of early adopters and high-volume users with higher approval rates, slightly more years in practice, and more cardiologists. Given that prescription approval rates for both PCSK9i and BA have now increased to >80% in our analysis, increasing uptake of novel LLT will require interventions to increase use among clinicians.
No takes yet. Share an insight, caveat, or question.
Hwang et al. (2025) conducted an observational in Clinicians prescribing lipid-lowering therapies. Novel lipid-lowering therapies (PCSK9i or BA) was evaluated on Prescriber uptake and approval rates. Although prescription approval rates for PCSK9i and BA have increased to >80%, the majority of US clinicians prescribing lipid-lowering therapies have never prescribed them.
Synapse has enriched 10 related papers. Consider them for comparative context: